Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers:: comparison of a systemic vs. a mucosal booster schedule
Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers:: comparison of a systemic vs. a mucosal booster schedule
复制标题
DOI：
10.1016/s0928-8244(03)00094-4
复制
发表时间：
2003-07-15
影响因子：
--
通讯作者：
von Specht, BU
中科院分区：
文献类型：
--
作者：
Göcke, K;Baumann, U;von Specht, BU
我们比较了免疫原性的两种疫苗接种方案，无论是系统或粘膜助推器，无论是在12名健康志愿者的铜绿假单胞菌（OprF-I）的重组外膜融合蛋白的粘膜初次接种。全身加强免疫诱导更高水平的IgG同种型OprF-I特异性血清抗体，平均+/- S.E.M. 32.6 +/- 7.8 X 10（7）酶联免疫吸附测定（ELISA）单位（EU），而鼻用加强剂为14.6 +/- 2.1 X 10（7）EU（P = 0.05）。特异性血清伊加抗体和唾液中的抗体在两个接种组之间没有差异。我们得出结论，联合粘膜/全身接种OprF-I疫苗可能会提供增强的全身免疫原性。需要进一步研究呼吸道表面的长期免疫原性和抗体诱导。(C)2003年，欧洲微生物学会联合会。由Elsevier Science B. V.出版，版权所有。
We compared the immunogenicity of two vaccination schedules with either a systemic or a mucosal booster, both following a mucosal primary vaccination with a recombinant outer membrane fusion protein of Pseudomonas aeruginosa (OprF-I) in 12 healthy volunteers. The systemic booster induced higher levels of OprF-I-specific serum antibodies of IgG isotype, with a mean +/- S.E.M. of 32.6 +/- 7.8 X 10(7) enzyme-linked immunosorbent assay (ELISA) units (EU) as compared to the nasal booster with 14.6 +/- 2.1 X 10(7) EU (P = 0.05). Specific serum IgA antibodies and antibodies in saliva did not differ between the two vaccination groups. We conclude that a combined mucosal/systemic vaccination with the OprF-I vaccine may offer an enhanced systemic immunogenicity. Further studies on the long-term immunogenicity and induction of antibodies on the respiratory airway surface are warranted. (C) 2003 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved.